Related Experiment Video

Updated: May 15, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Halting the allergic march

Hugo P Van Bever1, Sudesh T Samuel, Bee Wah Lee

  • 1From the Department of Pediatrics, National University Singapore, Singapore.

The World Allergy Organization Journal
|January 4, 2013
PubMed

Insights

Childhood allergic diseases like asthma are rising globally. Research suggests reduced early-life bacterial exposure may contribute, alongside genetics and environment, to these conditions.

Area of Science:

  • Allergy and immunology
  • Pediatric health
  • Environmental medicine

Background:

  • Childhood allergic diseases (asthma, rhinitis, atopic dermatitis) show a significant global increase.
  • In Singapore, asthma prevalence exceeds 20%, with 50% of children exhibiting allergy indicators.
  • Reduced early-life bacterial exposure is a potential factor in rising allergy rates, interacting with genetic and environmental influences.

Purpose of the Study:

  • To review current understanding of allergic sensitization, from prenatal to postnatal stages.
  • To explore the mechanisms behind the "allergic march" phenomenon.
  • To discuss prevention and treatment strategies for allergic diseases.

Main Methods:

  • Literature review of allergic sensitization.
  • Analysis of "allergic march" mechanisms.
  • Review of therapeutic interventions, including probiotics and immunotherapy.

Main Results:

  • Allergic sensitization occurs both prenatally and postnatally.
  • The "allergic march" involves a progression of allergic conditions.
  • Bacterial products (probiotics, prebiotics, synbiotics) and immunotherapy show potential in managing allergies.

Conclusions:

  • Allergic disease development is multifactorial, involving genetics and environment.
  • Understanding allergic sensitization and the "allergic march" is crucial for management.
  • Probiotics, prebiotics, synbiotics, and immunotherapy offer promising avenues for prevention and treatment.

More Related Videos

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Allergic Reactions02:06

Allergic Reactions

Overview
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...